Research programme: hepatitis B therapies - Precision BioSciences
Alternative Names: ARCUS-POL nucleases-Precision BiosciencesLatest Information Update: 08 Dec 2023
At a glance
- Originator Precision Biosciences
- Class Antivirals; Endodeoxyribonucleases; Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 30 Nov 2023 Preclinical development in Hepatitis B is ongoing in USA
- 10 Nov 2023 Pharmacodynamics and adverse event data from a preclinical trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral)